Global Hereditary Angioedema Market to Reach $5 Billion by 2030
The global market for Hereditary Angioedema estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$5 Billion by 2030, growing at a CAGR of 7.8% over the analysis period 2022-2030. C1 Esterase Inhibitors, one of the segments analyzed in the report, is projected to record 8.3% CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Selective Bradykinin B2 Receptor Antagonists segment is readjusted to a revised 7% CAGR for the next 8-year period.The U.S. Market is Estimated at $809.6 Million, While China is Forecast to Grow at 7.1% CAGR
The Hereditary Angioedema market in the U.S. is estimated at US$809.6 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$849.3 Million by the year 2030 trailing a CAGR of 7.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.Select Competitors (Total 46 Featured) -
- BioCryst Pharmaceuticals, Inc.
- CSL Ltd.
- iBio, Inc.
- Ionis Pharmaceuticals, Inc.
- Pharming Group NV
- Shire PLC
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioCryst Pharmaceuticals, Inc.
- CSL Ltd.
- iBio, Inc.
- Ionis Pharmaceuticals, Inc.
- Pharming Group NV
- Shire PLC
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 196 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2.7 Billion |
Forecasted Market Value ( USD | $ 5 Billion |
Compound Annual Growth Rate | 8.0% |
Regions Covered | Global |